Our research note today highlights the opportunities available from Basilea's existing portfolio and pipeline. Basilea addresses the...

Basilea announced this morning that it has received a further $25 million in non-dilutive funding from BARDA to support the development...

The H1 period at Basilea was notable for another strong performance from the anti-fungal Cresemba (isavuconazole). Underlying growth was...

Basilea announced this morning that it has acquired the global rights to the Phase 3-ready beta-lactam/beta-lactamase inhibitor,...

This morning, Basilea announced the start of its second Phase 3 trial for fosmanogepix, its first-in-class antifungal for the treatment...

Basilea has announced this morning that it has received a further $39 million from BARDA as a second instalment for the continued...